A Phase 3 interventional study of Symbicort Turbuhaler and Symbicort pMDI in Bronchial Asthma, sponsored by AstraZeneca. Completed at 50 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-08-15.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.
Among the 110 studies testing budesonide in Asthma, this one is the 19th largest by enrollment of the 108 interventional ones that give a count, is one of 12 that started in 2007, is one of 51 in phase 3, and was the 31st registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
University of British Columbia · Sites in Canada
Ages 19–49
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 51 · Phase 4 33
First in 1991; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 742 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 124 across the 108 interventional studies. Of the 94 that completed or were terminated, 35 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 110 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 48th largest by enrollment of the 248 interventional ones that give a count, is one of 18 that started in 2007, is one of 121 in phase 3, and was the 70th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
1 of the studies testing budesonide in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 110 studies testing budesonide in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of the this study is to evaluate the efficacy and safety of 2 actuations Symbicort®pMDI® 40/2.25 μg twice daily compared with1 inhalation Symbicort Turbuhaler® 80/4.5 μg twice daily and 1 inhalation Pulmicort®Turbuhaler® 100 μg twice daily for 6 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
Drug: Symbicort pMDI
Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
Drug: Symbicort Turbuhaler
Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
Drug: Pulmicort Turbuhaler
Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
Morning Peak Expiratory Flow (PEF)
Change in the Morning PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed
Time frame: Baseline to 6 weeks
Evening Peak Expiratory Flow (PEF)
Change in the Evening PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed
Time frame: Baseline to 6 weeks
Asthma Symptom Score, Night
Change in the Asthma Symptom Score (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.
Time frame: Baseline to 6 weeks
Asthma Symptom Score, Day
Change in the Asthma Symptom Score (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.
Time frame: Baseline to 6 weeks
Asthma Symptom Score, Total
Change in the Asthma Symptom Score (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.
Time frame: Baseline to 6 weeks
Percentage of Nights With Awakenings Due to Asthma
Change in the Percentage of Nights With Awakenings Due to Asthma from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. The participants answered "Yes" or "No" whether she/he woke up during the night due to asthma.
Time frame: Baseline and 6 weeks
Use of Rescue Medication, Night
Change in the Use of Rescue Medication (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed
Time frame: Baseline to 6 weeks
Use of Rescue Medication, Day
Change in the Use of Rescue Medication (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed
Time frame: Baseline to 6 weeks
Use of Rescue Medication, Total
Change in the Use of Rescue Medication (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed
Time frame: Baseline to 6 weeks
Percentage of Symptom-free Days
Change in the Percentage of Symptom-free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Symptom-free Day: no symptoms (asthma symptom score=0) night and day, and no awakenings due to asthma.
Time frame: Baseline to 6 weeks
Percentage of Asthma Control Days
Change in the Percentage of Symptom Control Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Asthma Control Day: no symptoms (asthma symptom score=0) night and day, no awakenings due to asthma, no rescue medication.
Time frame: Baseline to 6 weeks
Percentage of Rescue Free Days
Change in the Percentage of Rescue Free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Rescue-free Day defined as day and night with no use of rescue medication.
Time frame: Baseline to 6 weeks
Forced Expiratory Volume in 1 Second (FEV1)
Change in the FEV1from baseline to week 6 (calculated as a mean using all available data after randomization)
Time frame: Baseline to 6 weeks
898 subjects enrolled; 156 not randomised: 94 incorrect enrolment, 9 adverse events, 18 voluntary discontinuations, 1 lost to follow-up, 1use of not allowed medication, 1 non-compliant
| Milestone | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Started | 253 | 246 | 243 |
| Completed | 249 | 241 | 238 |
| Not completed | 4 | 5 | 5 |
| Withdrew: Adverse event | 3 | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 |
| Withdrew: Intake of prohibited conc. medication | 0 | 0 | 1 |
| Withdrew: Safety reasons | 0 | 0 | 1 |
| Withdrew: Other | 1 | 1 | 0 |
Change in the Morning PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed
| Liters/min | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Morning Peak Expiratory Flow (PEF) | 12.88 ± 24.6 | 13.78 ± 29.7 | 4.59 ± 27.9 |
Change in the Evening PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed
| Liters/min | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Evening Peak Expiratory Flow (PEF) | 12.34 ± 24.3 | 10.80 ± 29.1 | 1.43 ± 25.7 |
Change in the Asthma Symptom Score (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.
| Units on a scale | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Asthma Symptom Score, Night | -0.24 ± 0.41 | -0.27 ± 0.41 | -0.15 ± 0.39 |
Change in the Asthma Symptom Score (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.
| Units on a scale | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Asthma Symptom Score, Day | -0.21 ± 0.38 | -0.24 ± 0.40 | -0.15 ± 0.40 |
Change in the Asthma Symptom Score (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.
| Units on a scale | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Asthma Symptom Score, Total | -0.45 ± 0.73 | -0.51 ± 0.75 | -0.30 ± 0.73 |
Change in the Percentage of Nights With Awakenings Due to Asthma from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. The participants answered "Yes" or "No" whether she/he woke up during the night due to asthma.
| Percentage of night | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Percentage of Nights With Awakenings Due to Asthma | -14.0 ± 24.1 | -14.0 ± 26.4 | -8.3 ± 25.5 |
Change in the Use of Rescue Medication (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed
| Inhalations | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Use of Rescue Medication, Night | -0.41 ± 0.64 | -0.39 ± 0.76 | -0.19 ± 0.67 |
Change in the Use of Rescue Medication (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed
| Inhalations | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Use of Rescue Medication, Day | -0.21 ± 0.39 | -0.20 ± 0.47 | -0.13 ± 0.56 |
Change in the Use of Rescue Medication (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed
| Inhalations | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Use of Rescue Medication, Total | -0.62 ± 0.89 | -0.58 ± 1.09 | -0.32 ± 1.12 |
Change in the Percentage of Symptom-free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Symptom-free Day: no symptoms (asthma symptom score=0) night and day, and no awakenings due to asthma.
| Percentage of days | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Percentage of Symptom-free Days | 12.5 ± 23.7 | 15.3 ± 24.5 | 9.1 ± 21.2 |
Change in the Percentage of Symptom Control Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Asthma Control Day: no symptoms (asthma symptom score=0) night and day, no awakenings due to asthma, no rescue medication.
| Percentage of days | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Percentage of Asthma Control Days | 12.7 ± 23.6 | 15.1 ± 24.4 | 9.1 ± 21.2 |
Change in the Percentage of Rescue Free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Rescue-free Day defined as day and night with no use of rescue medication.
| Percentage of days | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Percentage of Rescue Free Days | 24.0 ± 30.9 | 26.2 ± 30.7 | 17.2 ± 28.4 |
Change in the FEV1from baseline to week 6 (calculated as a mean using all available data after randomization)
| Liters | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| Forced Expiratory Volume in 1 Second (FEV1) | 0.095 ± 0.328 | 0.147 ± 0.364 | 0.112 ± 0.326 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Symbicort pMDI | — | 0/253 (0%) | 0/253 (0%) |
| Symbicort Turbuhaler | — | 1/246 (0.4%) | 0/246 (0%) |
| Pulmicort Turbuhaler | — | 1/243 (0.4%) | 0/243 (0%) |
| Event | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler |
|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/253 | 1/246 | 1/243 |
| Age Continuous(years) | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler | Total |
|---|---|---|---|---|
| Mean | 41 (12 to 75) | 42 (12 to 76) | 39 (12 to 78) | 41 (12 to 78) |
| Sex: Female, Male(Participants) | Symbicort pMDI | Symbicort Turbuhaler | Pulmicort Turbuhaler | Total |
|---|---|---|---|---|
| Female | 152 | 142 | 131 | 425 |
| Male | 101 | 104 | 112 | 317 |
The record gives a start of Sep 2007, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol · Budesonide